HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity in this aggressive human model, the company said.
The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.
VTI and ITOT offer nearly identical market exposure, yet a few subtle differences set them apart. This piece highlights what those differences mean and how to decide which fund fits your long-term plan.
